Pacira BioSciences officer reports 3,960-share sale under 10b5-1 plan

Q: Is this Pacira BioSciences (PCRX) Form 4 filed by one or multiple reporting persons?

The Form 4 is indicated as filed by one reporting person , not by a group.

(Neutral)

(Negative)

Form Type

Rhea-AI Filing Summary

Pacira BioSciences, Inc. (PCRX) reported an insider stock sale by its Chief Medical Officer. On 11/17/2025, the officer sold 3,960 shares of Pacira common stock at a price of $24.09 per share, according to a Form 4 filing. After this transaction, the officer directly beneficially owned 178,367.009 shares of Pacira common stock.

The filing states that this sale was carried out under a Rule 10b5-1 trading plan, which is a pre-arranged plan for buying or selling stock that is intended to comply with securities regulations and provide an affirmative defense against insider trading claims.

Insider Trade Summary

Net Seller: 3,960 shares

Net Sell 1 txn

Insider SLONIN JONATHAN

Role Chief Medical Officer

Sold 3,960 shs ($95K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,960	$24.09	$95K

Holdings After Transaction: Common Stock — 178,367.009 shares (Direct)

Footnotes (1)

F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

FAQ

What insider transaction did Pacira BioSciences (PCRX) report in this Form 4?

The Form 4 reports that Pacira BioSciences' Chief Medical Officer sold 3,960 shares of Pacira common stock on 11/17/2025.

At what price were the Pacira BioSciences (PCRX) shares sold in the reported transaction?

The reported sale of Pacira BioSciences common stock was executed at a price of $24.09 per share.

How many Pacira BioSciences (PCRX) shares does the insider own after the sale?

Following the reported transaction, the Chief Medical Officer beneficially owned 178,367.009 shares of Pacira BioSciences common stock directly.

Who is the reporting person in this Pacira BioSciences (PCRX) Form 4?

The reporting person is an officer of Pacira BioSciences serving as Chief Medical Officer.

Was the Pacira BioSciences (PCRX) insider sale made under a Rule 10b5-1 plan?

Yes. The filing explains that the sale was effected pursuant to a previously adopted Rule 10b5-1 trading plan.

Is this Pacira BioSciences (PCRX) Form 4 filed by one or multiple reporting persons?

The Form 4 is indicated as filed by one reporting person, not by a group.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/19/2025 - 04:32 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SLONIN JONATHAN

(Last)

(First)

(Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE

94005

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/17/2025		S		3,960⁽¹⁾	D	$24.09	178,367.009	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR